Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Trial Information

Randomized Phase II Trial of Idarubicin + Ara-C +/- Bevacizumab in Patients Age < 60 With Untreated Acute Myeloid Leukemia

PRIMARY OBJECTIVES:

I. Compare the activity of idarubicin and cytarabine with or without bevacizumab in patients
with newly diagnosed acute myeloid leukemia.

II. Compare the proportion of patients who survive and remain in first complete remission
(CR) one year from achieving CR after treatment with these regimens.

SECONDARY OBJECTIVES:

I. Compare the safety of these regimens in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to age
(< 45 vs 45 to 59), cytogenetics (normal vs -5/-7 vs other), flt 3 status (normal vs
mutated), and type of acute myeloid leukemia (AML) (de novo vs secondary [arising after
cytotoxic therapy or after an antecedent hematologic disorder, defined as a documented
abnormality in blood count for >= 3 months before diagnosis of AML]. Patients who require
treatment before cytogenetics or flt 3 status is known (e.g., patients with WBC > 50,000 OR
with organ dysfunction thought to be due to blast infiltration) are stratified only
according to age and type of AML. Induction therapy: Patients are randomized to 1 of 2
treatment arms.

Arm I: Patients receive idarubicin IV over 1 hour on days 1-3 and cytarabine IV continuously
over 24 hours on days 1-4.

Arm II: Patients receive idarubicin and cytarabine as in arm I. Patients also receive
bevacizumab* IV over 30-90 minutes on day 1. Patients who do not achieve complete remission
(CR) after the first induction course may receive a second induction course approximately 28
days* later. Patients who do not achieve CR after 2 courses are removed from the study.

NOTE: *Patients in arm II receive bevacizumab, independently of chemotherapy administration
schedule, once every 21 days for 1 year from CR date.

Post-CR therapy: All patients receive 4 post-CR chemotherapy courses approximately every 28
days in the absence of disease progression or unacceptable toxicity.

Course 1: Patients receive cytarabine IV continuously over 24 hours on days 1-5.

Course 2 and 4: Patients receive idarubicin IV over 1 hour and cytarabine IV continuously
over 24 hours on days 1-4.

Course 3: Patients receive idarubicin IV over 1 hour and cytarabine IV continuously over 24
hours on days 1-2. After completion of the 4 post-CR chemotherapy courses, patients in arm I
induction therapy do not receive further therapy. Patients in arm II induction therapy
continue to receive bevacizumab as described above.After completion of study treatment,
patients are followed every 3 months for 2 years.

PROJECTED ACCRUAL: A total of 60-120 patients (30-60 per treatment arm) will be accrued for
this study within 12-30 months.

Inclusion Criteria:

- Newly diagnosed acute myeloid leukemia (AML)

- No acute promyelocytic leukemia

- None of the following cytogenetic abnormalities*:

- t(8;21)

- t(16;16)

- inv(16)

- No history or clinical evidence of primary brain tumors or brain metastasis

- Performance status - ECOG 0-2

- No bleeding diathesis or coagulopathy (unless related to AML)

- Bilirubin ≤ 2.0 times upper limit of normal (ULN)

- ALT ≤ 2.5 times ULN

- Creatinine ≤ 2.0 times ULN

- No proteinuria

- No more than 1 g of protein on 24-hour urine collection

- LVEF ≥ 50%

- No uncontrolled hypertension

- No New York Heart Association class II-IV congestive heart failure

- No serious cardiac arrhythmia requiring medication

- No peripheral vascular disease ≥ grade II

- No stroke within the past 6 months

- No arterial thromboembolic event within the past 6 months, including any of the
following:

- Transient ischemic attack

- Cerebrovascular accident

- Myocardial infarction

- Unstable angina

- No other clinically significant cardiovascular disease

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for at least 3-4 months
after study participation

- No serious or non-healing wound ulcer or bone fracture

- No uncontrolled infection

- No significant traumatic injury within the past 28 days

- No known hypersensitivity to Chinese hamster ovary cell products or other recombinant
human antibodies

- No history or clinical evidence of CNS disease (e.g., seizures not controlled with
standard medical therapy)

- Prior or concurrent transfusions or hematopoietic growth factors for AML allowed

- No concurrent prophylactic hematopoietic colony-stimulating factors

- Prior or concurrent hydroxyurea for AML allowed

- More than 28 days since prior major surgery or open biopsy

- No concurrent major surgery

- No other prior therapy for AML

- No concurrent full-dose anticoagulation therapy

- Concurrent prophylactic anticoagulation (e.g. low-dose warfarin to maintain
patency of permanent indwelling IV catheters) allowed provided INR < 1.5

- No other concurrent anticancer therapies

- No other concurrent investigational cytotoxic agents

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Proportion of patients who remain alive in the first complete remission (CR) 1 year from achievement of CR assessed every 3 weeks for 1 year

Outcome Description:

Fisher's exact test will be used to compare the proportion of patients alive in CR 13 months from registration date. The test has approximately 89% power to detect an absolute increase of 20% in this proportion, testing at the one-sided 0.15 significance level.

Outcome Time Frame:

13 months from registration

Safety Issue:

Principal Investigator

Srdan Verstovsek

Investigator Role:

Principal Investigator

Investigator Affiliation:

M.D. Anderson Cancer Center

Authority:

United States: Food and Drug Administration

Study ID:

NCI-2012-02627

NCT ID:

NCT00096148

Start Date:

October 2004

Completion Date:

Related Keywords:

Adult Acute Basophilic Leukemia
Adult Acute Eosinophilic Leukemia
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myelomonocytic Leukemia (M4)
Adult Erythroleukemia (M6a)
Adult Pure Erythroid Leukemia (M6b)
Childhood Acute Basophilic Leukemia
Childhood Acute Eosinophilic Leukemia
Childhood Acute Erythroleukemia (M6)
Childhood Acute Megakaryocytic Leukemia (M7)
Childhood Acute Monoblastic Leukemia (M5a)
Childhood Acute Monocytic Leukemia (M5b)
Childhood Acute Myeloblastic Leukemia With Maturation (M2)
Childhood Acute Myeloblastic Leukemia Without Maturation (M1)
Childhood Acute Myelomonocytic Leukemia (M4)
Secondary Acute Myeloid Leukemia
Untreated Adult Acute Myeloid Leukemia
Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Congenital Abnormalities
Neoplasms
Leukemia
Leukemia, Basophilic, Acute
Leukemia, Eosinophilic, Acute
Leukemia, Erythroblastic, Acute
Leukemia, Megakaryoblastic, Acute
Leukemia, Monocytic, Acute
Leukemia, Myeloid, Acute
Leukemia, Myeloid
Leukemia, Myelomonocytic, Acute
Leukemia, Myelomonocytic, Chronic
Hypereosinophilic Syndrome

Name	Location
M D Anderson Cancer Center	Houston, Texas 77030

Join the Community

Join the Directory

Trial Information

Inclusion Criteria:

Type of Study:

Study Design:

Outcome Measure:

Outcome Description:

Outcome Time Frame:

Safety Issue:

Principal Investigator

Investigator Role:

Investigator Affiliation:

Authority:

Study ID:

NCT ID:

Start Date:

Completion Date:

Related Keywords:

Name

Location